OmniAb, Inc. (OABI) Earnings Call Transcript & Summary
November 12, 2024
Earnings Call Speaker Segments
Kurt Gustafson
executiveThanks, operator, and good afternoon, everyone. Kurt Gustafson here, OmniAb's Chief Financial Officer. I appreciate all of you for being with us on this conference call covering our financial results for the third quarter of 2024. Slides have been prepared to go along with today's remarks, and you can find them in the Investors section of our website, www.omniab.com. Before getting started, I want to remind those listening that remarks management makes on this call will contain forward-looking statements under the meaning of federal securities laws; such forward-looking statements carry risks and uncertainties that might lead actual results to differ materially from any results anticipated. Our cautionary statements in today's press release and our SEC filings qualify these forward-looking statements. Importantly, this conference call includes time-sensitive information that is accurate only as of today's live broadcast date, November 12, 2024. Except as the law requires, OmniAb assumes no obligation to revise or update any forward-looking statements to reflect events or circumstances arising after this call's date. With me on the call today is Matt Foehr, OmniAb's President and Chief Executive Officer; and during today's call, Matt and I will offer highlights regarding the company's operations, updates on partners and technology and our recent financial results. Once the prepared remarks conclude, we'll open the call to questions. And with that, let me hand the call over to Matt.
Matt Foehr
executiveThank you, Kurt. Hello, everyone, and I appreciate you being with us this afternoon for our call covering the third quarter; we have kept up delivering solid results on our main metrics and are gaining momentum within the business. Thanks to robust implementation and a business model that scales well, we are positioned favorably to handle many different industry cycles, with a company that is now set up to succeed. Our varied roster of partners and programs keeps expanding and did expand throughout Q3 even though the macro backdrop has been rather difficult, creating headwinds this year for certain parts of the pharma discovery tools and technology sector. As clinical stage programs from our partners move forward, we are likewise obtaining improved visibility into the schedule of important inflection points for preclinical as well as later-stage programs. Such post-discovery programs make up only a portion of our expanding portfolio and carry more than $550 million in possible milestones for OmniAb. We are dedicated to fueling innovation so we can further set our technologies apart and strengthen our pipeline, and we are enthusiastic about both the prospective opportunities that lie ahead and the significant role we play in the worldwide pharmaceutical industry. Let me now briefly go over a few of our business metrics, beginning on Slide #5. On the left-hand chart displayed here, you can see that we closed Q3 having 86 active partners. During the quarter, we entered into 3 new platform license agreements, among them new deals with 92Bio, Memorial Sloan Kettering Cancer Center and Queen Mary University of London. Solid partnerships such as these are essential to what we do, and we stay dedicated to growing our partner base while assisting partners in achieving their research and discovery objectives. In addition, I want to note that we recently broadened our ion channel screening arrangement with Syngenta, which started last year; and we also recently signed a new license with Incyte Corporation. We aim to close out the year on a high note with respect to our business development and licensing work, and in that respect, this year may turn out to be our strongest ever. The rise in our partner count demonstrates the industry's curiosity about our technology as well as our commitment to innovation and teamwork. Through cultivating these connections, we think we are generating fresh possibilities for shared success. And one extra upside is that our close ties with partners assist in guiding the smart growth of our platform. Our partnerships give us a useful perspective on present industry shifts and upcoming chances and also keep OmniAb at the forefront of sought-after technologies. The count of active programs being run by our partners stays healthy, and new program additions so far this year have been impressive. On Slide #6 here, you can see that as of September 30, active programs grew to 352 net of attrition. On this slide, you will notice that we now offer additional detail regarding our active programs. We are showing both attrition and additions on the right-hand portion of the slide in the call-out bar graph that appears on screen, using the orange and the green bars. At the close of the third quarter, we had 12 terminations and 39 active program additions. It's something we say pretty regularly: programs ending or partners walking away is just part of what happens in drug development. And like we've pointed out this year — and like the wider industry has reported — a number of pharma companies keep reshuffling and re-ranking their pipelines and therapeutic programs. That said, when you look at how many active programs we have, the net figure keeps going up, and that's a real endorsement of our technology platform; we've been net positive even after losing programs, and we've done that across several years and through all sorts of macroeconomic and industry swings, which I'd say shows we can keep evolving and improving our technologies and reaching further. Like I said on the slide before this one, the strong ties we have with our partners put us in a great spot as we direct where our innovation goes; and now we're on Slide 7. When September 30 came around, there were 33 active clinical programs plus approved products across our partners. This quarter, two things moved into Phase I trials: GEN1057 from Genmab, which is an investigational bispecific antibody they own, and M5542 from Merck KGaA, a fusion protein. GEN1053, also from Genmab, dropped off the clinical program tally you see on this slide and went back to preclinical. Genmab has said publicly that they're stopping a Phase I/II solid tumor trial for GEN1053, though preclinical work continues in other indications. By the close of Q3, 3 programs derived from OmniAb had started human trials during 2024. From what our partners tell us, we still anticipate 1 to 3 more novel OmniAb-derived antibodies will enter clinical development before the year is out. The assets we have past discovery — preclinical ones and those in later stages — could generate value both near term and midterm. Now on Slide #8, you can see that this asset count has grown. Across the last 2 years, the growth has been impressive, with those programs up 40%, hitting 53 in total by the close of Q3. Like I said before, the programs shown here carry more than $550 million in potential milestones contracted to OmniAb. When our partners' programs move forward successfully, it highlights the work we do together and the vision we share, plus the value our technologies are capable of creating; and on Slide #9 here, I'll quickly go over a few chosen partner updates. Immunovant has moved IMVT-1402 forward considerably; and late last week, they said the IND for rheumatoid arthritis had cleared, noting that for hard-to-treat RA, IMVT-1402 may have a best-in-class profile. They also said the FDA has cleared 5 INDs across a variety of therapeutic uses, and that they expect to start potentially registrational trials for IMVT-1402 in 4 to 5 indications by the close of Q1 next year. On top of that, they shared positive Phase IIa results for batoclimab in Graves' disease. They further announced that they've aligned with the FDA, that an IND has cleared, and that they expect to launch a pivotal trial of IMVT-1402 in Graves' disease before this year ends. On last week's earnings call, Genmab also brought attention to acasunlimab along with GEN1057. Their stated priority is to keep developing a pipeline that is world-class and differentiated, and they pointed to the Phase III trial of acasunlimab in second-line non-small cell lung cancer, noting that it remains on schedule to begin during this year. In addition, they called attention to the Phase I/II study of GEN1057 in malignant solid tumors, which has recently gotten underway. Over at the ESMO conference, BioCity shared interim Phase I clinical data regarding the safety and efficacy of BC-3195, its first-in-class antibody drug conjugate aimed at CDH3; according to their report, 3195 showed striking antitumor activity among patients suffering from advanced non-small cell lung cancer, and the therapy is currently in parallel dose optimization and dose expansion studies across China; meanwhile, Teva recently made public Phase I results for TEV-53408, an anti-IL-15 that came out of our OmniRat technology. Per Teva, 408 appears to have a potential best-in-class profile, with high affinity for IL-15, extended suppression of free IL-15, and the possibility of infrequent dosing. In a first-in-human study it was well tolerated, and a proof-of-concept trial in celiac disease is currently underway. Teva also revealed last week that a clinical study has begun in vitiligo, an autoimmune condition where substantial unmet medical need exists. Now, on my final slide, Slide #10, I want to call attention to a few scientific conferences our team has coming up. By presenting innovations that we believe generate value for our partners, we keep raising the profile of our differentiated technology platforms at the scientific conferences that matter. We will be in San Diego next month for the Antibody Engineering and Therapeutics Conference, where members of our team will showcase workflows for finding developable binders that offer broad epitope coverage and affinities, serving as building blocks for multispecifics — a space seeing considerable and expanding interest across the industry. During a separate presentation, we will cover the design and implementation of OmniHub, a new platform we are introducing for bioinformatics tools that further improves antibody discovery workflows by combining machine learning and AI tools with our extensive bioinformatics know-how. At the start of the year, we noted that we would be introducing several partner experience improvements, and OmniHub serves as one such example; so with that, I will hand the call over to Kurt now so he can walk through our third quarter financials. Kurt?
Kurt Gustafson
executiveThanks, Matt. On Slide 12, the income statement breaks down how we did financially during 2024's third quarter. Revenue came in at $4.2 million for that quarter, compared with $5.5 million during the same quarter last year. The drop stemmed mainly from reduced milestone revenue along with weaker Ion channel service revenue. Earlier, we had told you that our revenue would be weighted toward the second half of the year. That outlook rested on statements and information provided by our partners, and we still think it holds true. That said, it appears the bulk of those milestones will land in the fourth quarter. R&D expense during the third quarter reached $13.3 million, versus $13.9 million in the same quarter a year earlier, with the decline largely attributable to reduced stock-based compensation expense. G&A expense came to $7.1 million for the quarter, compared with $8.5 million a year ago, with the drop mainly driven by lower legal costs and reduced stock-based compensation. Our operating expenses match what we expected, and we continue to expect total operating expenses for 2024 to come in slightly below total operating expenses for 2023. Net loss for 2024's third quarter totaled $16.4 million, or $0.16 per share, against a net loss of $15.7 million, or $0.16 per share, during the prior year period. If you turn to Slide 13, you'll find our balance sheet as of September 30, 2024; we closed the third quarter holding $59.4 million in cash, which includes $8.5 million of capital raised through our at-the-market security offering. We brought in another $2.9 million under the ATM program after the quarter ended, and that will show up in our fourth quarter financial statements. Throughout the year, we kept seeing pressure on the biopharmaceutical industry, which has resulted in restructurings and pipeline reprioritizations. That can create added volatility in our business; and with those dynamics in mind, we felt it was prudent to build some cushion into our balance sheet by issuing stock through our ATM program. These new funds bolster our cash position, improve our financial and strategic flexibility and better ready us for potential risks arising from macroeconomic and shifting industry conditions and cycles. Right now, we believe the company is well capitalized, and we're heading into 2025 in a stronger financial position; on cash guidance, we expect to finish 2024 with a cash balance ranging from $50 million to $60 million, which factors in the proceeds from the recent ATM issuance. We expect certain development milestones to be reached during the fourth quarter. That said, because our contracts' payment terms usually fall between 30 and 60 days, the cash we actually collect on a portion of those milestones might not come in until Q1 of the following year, and that's the reason the range is so wide; as for our 2025 cash guidance, based on how we currently anticipate our already-partnered pipeline will advance, we expect cash used during 2025 to come in below 2024 levels, not counting the proceeds from the recent ATM program. With that, I'd like to turn the call over to questions. Operator?
Michael Almisry
analystMicheal is filling in for Puneet right now. Nice work on the quarter. Given how big the jump in active programs was this quarter, I wanted to ask whether you could shed some light on how much of that comes from a broader macro rebound across biopharma, versus what you're doing yourselves — perhaps picking up share or growing in particular geographies?
Matt Foehr
executiveSure, Micheal, I appreciate the question. It's Matt here. Right. Let me point to one thing that you probably already noticed, but we decided to share a bit more granularity on the count of active programs after talking it over with our internal group and outside stakeholders, who felt it would be helpful. In the past we only gave figures net of attrition, whereas today we're also giving more detail on additions and attrition. Program count growth has been robust this year, and it remains robust. I see that as evidence of the fresh technologies we've rolled out. Our OmniAb technology — genuinely the first and only transgenic chicken capable of producing single-domain antibodies, a novel antibody class discovered naturally in Camelids and an area drawing rising interest within the industry for numerous scientific reasons. We're seeing plenty of interest there; that's fueling many new starts; and beyond that, I'd add that platform validation plays a role too. We weigh that against the industry backdrop, including some items we brought up in the intro about large pharma firms realigning portfolios and pipelines and so on. Still, program growth has been robust and remains so.
Michael Almisry
analystAll right, that's excellent. And next, I wanted to ask briefly about OmniHub. My curiosity was whether this is yet another add-on included within a standard license, or whether it will function as a separate software revenue stream?
Matt Foehr
executiveYeah, thank you. This is one more instrument we employ when working alongside our partners, correct? So a complete rollout is planned for the ATC conference taking place in December in San Diego. And truly, its purpose is to help enable, streamline, and speed up discovery-related interactions together with our partners. Having grown our platform, we gain the advantage of a foundational technology — our transgenic animals — which generate quite robust antibody responses, opening doors for us to apply machine learning, AI, and big data analysis in manners that, honestly, competitors cannot. And OmniHub lets us engage with our partners as a means of supporting their downstream work. Thus, it belongs to our standard offering. We don't view it as necessarily being its own business line item, though it's among the methods through which we keep innovating and stay at the forefront to serve our partners' requirements both currently and going forward.
Matt Hewitt
analystThis is <<inaudible>> joining the call in place of Matt Hewitt. We've picked up some chatter that although biotech has risen this year versus last, the capital brought in has fallen off from what it was earlier in the year through the most recent quarter. Consequently, a number of companies are exercising a bit more restraint when it comes to their investments. Are you picking up on anything along those lines?
Kurt Gustafson
executiveYes. I believe we kind of brought up that a few of these macro and industry forces are things we're watching. I'd say it's — what you're describing and seeing is what we're seeing too. And without question there's pressure that has built up on the industry, and as we discussed a bit, that has produced some of the volatility in our business. So perhaps our outlook going forward is a touch more cautious. That said, I think if you look at the key metrics we've concentrated on when it comes to signing new deals, partners still recognizing the value of our technology and launching new programs, moving things along through the clinic, progress is showing up across all of our key metrics. So I'm not dismissing the fact that there are some difficult industry things happening, but our business keeps performing well. Matt, anything to add on that?
Matt Foehr
executiveNot truly. The one point I would make is that we discussed the way certain bigger pharmaceutical companies have undertaken what they refer to as "portfolio shaping initiatives," that sort of thing. Yet that gets offset by — we engage in many conversations with people in the industry. And something else we hear is that when they are concentrating their efforts, they also seek out the strongest platforms and the technologies with the most validation to assist them in fulfilling their discovery requirements, and that too can draw them toward us; so indeed, much is happening across the industry, but we are pleased with where we stand.
Analyst
analystGreat. I understand it's still early, but when it comes to the number of new clinical entries from your partners, how should we think about that range for next year?
Matt Foehr
executiveYes. Thank you. That's a good question. As we think about next year—and like we've mentioned—we're expecting 1 to 3 additional clinical entries prior to the close of this year, correct? So within roughly the coming 6 weeks, based on what our partners have told us. And if you look at our post-discovery assets, at present we hold 20 assets in preclinical; our standard for what counts as a preclinical asset is quite high. Those programs, then, are candidates for entering the clinic in 2025. My expectation is that once we're into next year, we'll discuss that with more detail. What we frequently see is that the JPMorgan conference in early January is frequently a moment when a lot of our partners begin speaking more openly about new programs, new trials, new indications, and what they intend for the year. So around then, or after then, is frequently a good moment for us to begin speaking with a bit more specificity about certain programs and the count we anticipate. But we feel good about the portfolio's growth and how the programs are matriculating through the various phases.
Stephen Willey
analystSo I suppose what you're describing is that program count growth continues to be robust. You brought up that multispecifics represent a significantly expanding segment for the sector. Are you able to tell what share of newly launched programs are multi-specific in nature? Can you provide that kind of detail? And do you additionally possess any understanding of which targets partners are going after through these newly initiated programs? I suppose I'm simply curious whether you can evaluate roughly where every yearly batch of newly launched programs lands on the risk spectrum.
Matt Foehr
executiveYes. Thanks, Steve. Excellent question; and what I'd say is that it varies, correct? Yet as our platform has grown more broadly adopted and more thoroughly validated, the count of novel modalities and approaches that partners seek to apply downstream, using our technology for antibody discovery, keeps expanding. And even if you examine just our visible clinical programs, an increasing share of those are bispecifics, correct? Multi-specifics are undoubtedly the coming wave, and we've witnessed a rise in multispecifics this year along with enthusiasm there. And I believe our OmniAb technology is fueling that too. We're additionally observing greater diversification in therapeutic areas and fields of interest. OmniAb creates far more opportunities in neuroscience and in oncology, where we already maintain a fairly extensive footprint. So I'll respond in a broad way and say it's definitely heightening interest in multispecifics. And we're glad that partners approach us since they recognize we possess technologies built to address the requirements there. That's something we've discussed with them for quite a while. So they understand that we're available and our technologies are crafted to help fulfill that requirement.
Stephen Willey
analystAll right, that's useful. So then, I believe you might have shared this at some point in the prior year, but is there any fresh detail on what the blended royalty rate for the post-discovery program portfolio currently stands at? And beyond that, can you tell us anything regarding how the Immunovant 1402 asset, I suppose, stacks up against that blended royalty rate? I'm aware this asset is drawing quite a bit of investor interest at the moment.
Kurt Gustafson
executiveYeah. Steve, on that blended royalty rate, I have nothing new to share. We disclosed that figure, when was it, around September, November of the prior year. What I can tell you, though, is the rate we gave was tied to how many active programs existed at that point, roughly 300. Clearly, our count of active programs has risen, yet shifting that figure substantially is rather difficult. So even though I can't offer a fresh figure, my guess is it isn't dramatically different from what we shared back in November. Regarding the Immunovant program, just to recap, the structure of that contract is that Henal was the initial counterparty we held an agreement with. So how it functions is Immunovant pays Henal, and we receive a share of what Henal receives. Consequently, it's somewhat unlike a direct license arrangement for us; however, on the royalty rate, what we typically say is that the royalty rate we receive falls within the low to mid-single digits. And it happens that the percentage we'll collect from Henal, which they collect from Immunovant, aligns fairly well with that. So I probably can't go further than that when it comes to disclosing that rate. Still, I hope that proves somewhat useful regardless.
Alex Xenakis
analystAlex here, filling in for Kripa. We've got a question. Some of the partners you work with appear to be reassessing their pipelines, possibly because of economic strain. So are you noticing more or fewer partners choosing to build molecules internally and push them through to the IND stage? What's your take on that? And does any of this create an effect, or can we spot early signs of a shift that could influence how your business model works down the road?
Matt Foehr
executiveYeah. Appreciate it, Alex. For your second question, here's a brief response. No, our business model feels solid to us, as does the leverageability within our business, our capacity to show that moving forward, and our standing in the industry overall. Partners approach us specifically for discovery technologies; taking programs into IND isn't something we aim to do. They seek us out so they can tap into our technologies, which give them access to wide repertoires of novel antibodies and let them rapidly pick winning antibodies to carry forward. Given our close relationships with partners, we hold a distinctive view of the industry — we grasp which targets they pursue and how they prefer to engage those targets. That shapes the way we innovate around our early-stage discovery platform. So yeah, I don't foresee any shift in how our business model works; the work we're doing and our place in the industry feel great to us. And I believe we have a business well positioned to weather multiple industry cycles. That's intentional by design. And I really don't see us faltering because of that.
Jacqueline Kisa
analystThis is Jackie filling in for Brandon. To kick things off, has any beta testing been conducted for the OmniHub offering ahead of launch? And if that's the case, has any customer feedback come through?
Matt Foehr
executiveYeah. Jackie, obviously we're interacting with our partners digitally on a constant basis, so I suppose the quick response there is yes. And we — as our bioinformatics capabilities have grown across the years and then introduced our OmniDeep platform during the past 2 years, which is a suite of in silico tools; this genuinely turned into a very natural outgrowth of what we're doing. So the brief answer is affirmative, we engage with partners digitally in that manner, and we'll be introducing sort of the brand and more widely at the ATC conference in December.
Jacqueline Kisa
analystWonderful, that's excellent. And to build on that point. Are you considering teaming up with any cloud providers? Or will you sort of handle operations on-prem or in your own environment?
Matt Foehr
executiveRight. Right now, far more self-developed. Clearly, plenty of other IT infrastructure exists behind the scenes, yet it's far more self-developed right now.
Jacqueline Kisa
analystGreat, and let me fit in one final question if I can. Regarding those three new licenses, could you share any detail about what therapeutic areas these companies are interested in, how big the programs might be, and what the breakdown looks like for the platforms they plan to use?
Matt Foehr
executiveSure. During the quarter we disclosed three new agreements. The first is with 92Bio, a business whose entire focus is on cancer and on multi-specific antibodies designed to be best-in-class, so their attention will be on cancer targets. The remaining two agreements were signed with Memorial Sloan Kettering Cancer Center. As everyone knows, their commitment to cancer is deep and has lasted a long time, they direct substantial funding toward translational research, and they operate a sizable innovation hub. Their main emphasis is clearly on novel cancer targets. Then there's Queen Mary University of London, which is, naturally, a leading research institution in the U.K. Their focus is really on preventing cancer along with diagnostics and theranostics. Those happen to be fields where certain of our newer technologies fit quite nicely. So overall, there's a variety of our technologies that these organizations will want to work with, very much like so many of our existing partners. We're therefore pleased to bring them aboard.
Conor McNamara
analystI have a question for both of you. Matt, from the perspective of product development, what developments are you observing with single-domain antibodies? And what are you observing regarding customer adoption of OmniChicken?
Matt Foehr
executiveSure. Mainly regarding the single domain aspect, clearly, we introduced our OmnidAb technology roughly 12 months back. And it has represented a very meaningful share of one of the factors drawing in new partners. And it unlocks fresh opportunities spanning a variety of therapeutic areas. I brought up expansion in the CNS space; that is a major one, along with radiotherapy. There is considerable interest in that area, and that is bringing in many new partners. Interest also exists in infectious diseases too. And that is something where we have had certain partnerships previously, but that has certainly sped up as well. Many different factors are fueling this, the variety of administration routes that single-domain antibodies create the chance for, whether that is injectable, inhalable or oral, the capacity to cross the blood-brain barrier and achieve rapid or adjustable clearance; that is another component drawing in new partners. And then a field I am enthusiastic about is simply this expansion into new areas. As I mentioned, the diagnostics, the theranostics, radiotherapy; so indeed, it has generated greater diversity within our pipeline of programs, which we are thrilled about.
Conor McNamara
analystAll right, that's helpful. So Kurt, regarding the ATM, the capital you brought in — it was slightly above $11 million. When I consider that alongside what seems like a delay, and what you anticipate from license and milestone revenue, should we view that roughly $11 million as funds that could have arrived prior to the close of '25 but now, due to program timing, you're indicating might slip a bit later? Or can you break out how much of that relates purely to SafetyNet versus what you regard as later-than-planned revenue from those sources?
Kurt Gustafson
executiveYeah. No, Conor, my view is this wasn't connected to covering some particular gap we foresaw arising in the present quarter or anything similar, or even the following quarter. As the year went on, we simply — we noticed both large pharma and smaller businesses, given shifts across the industry plus funding cycles and similar factors; we became somewhat more careful regarding our outlook and decided it likely makes sense to add a modest cushion to the balance sheet. So I'd characterize the whole amount as being more about, looking ahead, let's place a small cushion on the balance sheet so we can be confident we hold sufficient capital to navigate the different cycles that could arise. Therefore it wasn't, hey, we'll come up $3 million short this quarter, let's go use the ATM; it reflected more of a longer-term perspective.
Conor McNamara
analystCongratulations, everyone, on how the business has been advancing.
Matt Foehr
executiveWonderful. Thank you. I want to express my appreciation to all of you for being on this call today, and thank you for your questions. We're eager to continue sharing news about where we stand and to bring you another update when the next quarter arrives. Kurt and I are scheduled to attend two investor conferences in the coming week. Kurt's destination is New York, where the Stifel Healthcare Conference is taking place, while I'll be heading to London for the Jefferies Conference. Until then, we're grateful for the attention you've shown toward OmniAb, and once more, thank you for being with us today.
Operator
operatorEveryone, that brings us to the end of today's call. We appreciate you joining us. You're free to hang up now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete OmniAb, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to OmniAb, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in OmniAb, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.